Skip to content

A Multicenter Randomized Controlled Trial of White Light Therapy for Perinatal Depression

A Multicenter Randomized Controlled Trial of White Light Therapy for Perinatal Depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118746
Enrollment
Unknown
Registered
2026-02-10
Start date
2024-09-11
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perinatal Depression

Interventions

Part2-Placebo light prevention group:Placebo Light Smart Desk Lamp with Illumination Intensity <250 LUX
Part 1 - Individualized White Light Intervention Group:Smart light therapy lamp that activates illumination precisely 8.5 hours after the onset of individual melatonin secretion
Part 1- Traditional White Light Group:Intelligent lighting desk lamp that turns on based on the self-reported daily habitual wake-up time
Part 2 - White Light Prevention Group:Smart Desk Lamp with Standard White Light at 10,000 Lux Illuminance

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Currently meets the diagnostic criteria for perinatal depression in DSM-5 and M.I.N.I., with a Hamilton Depression Rating Scale (HAMD-17) score >=17; 2. Age >= 18 years; 3. At least a primary school education with normal communication and comprehension skills; 4. Willing to participate in this study, able to cooperate with follow-up visits, and sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1. Patients with severe physical illnesses (such as significant impairment of cardiopulmonary, hepatic, or renal function; fractures); 2. Patients with ocular conditions such as cataracts or glaucoma, or those taking photosensitizing medications; 3. Patients with comorbid psychiatric disorders (psychiatric disorders caused by organic diseases, bipolar disorder, schizophrenia, substance dependence, etc; 4. Patients with implanted pacemakers, undergoing defibrillation, or experiencing other arrhythmias (e.g., unstable and/or irregular heart rhythms such as atrioventricular block, multiple premature beats, atrial flutter, atrial fibrillation).

Design outcomes

Primary

MeasureTime frame
Improvement in depression severity;Fetal and Neonatal Outcomes;Infant Outcome;

Secondary

MeasureTime frame
Risk of Mania;Autonomic nervous system function;Suicide risk;Autonomic nervous system function;Circadian Rhythm;Circadian Rhythm;Sleep quality;

Countries

China

Contacts

Public ContactDu Lian

The First Affiliated Hospital of Chongqing Medical University

fmridul@126.com+86 23 89012959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026